Table I.

Characteristics of the included trials.

	Patients (n)		Intervention
Study	Experimental	Control	Experimental	Control	Duration (weeks)	Outcomes
Brandt et al 2003 (26)	14	16	ETN	PBO	6	ASAS 20, ASAS 50, BASDAI, BASDAI 50, BASFI, AEs
Calin et al 2004 (24)	45	39	ETN	PBO	8	ASAS 20, ASAS 50, ASAS 70, AEs
Davis Jr et al 2003 (22)	138	139	ETN	PBO	24	ASAS PR, BASDAI, BASFI, OW, CRP, AEs
Gorman et al 2002 (21)	20	20	ETN	PBO	16	OW, AEs
Deng et al 2009 (29)	26	26	ETN	PBO	6	ASAS 20, ASAS 50, ASAS 70, BASDAI 50, AEs
Dougados et al 2011 (19)	39	43	ETN	PBO	12	BASDAI, BASDAI 50, BASFI, ASAS PR, CRP, AEs
van der Heijde et al 2006 (25)	150	51	ETN	PBO	12	BASDAI 50, ASAS PR, AEs
Huang et al 2010 (28)	74	78	ETN	PBO	6	ASAS 20, ASAS 50, ASAS 70, BASDAI, BASFI, AEs
Huang et al 2011 (27)	300	100	ETN	PBO	6	ASAS 20, BASDAI 50, ASAS PR, AEs
Lin et al 2010 (20)	19	20	ETN	PBO	6	ASAS 20, ASAS 50, ASAS 70
Zhang et al 2009 (30)	43	43	ETN	PBO	6	ASAS 20, ASAS 50, ASAS 70, BASDAI 50, ASAS PR
Braun et al 2011 (23)	378	187	ETN	SSZ	16	ASAS 20, BASFI, ST, CRP, AEs
Chen et al 2010 (35)	20	20	ETN	SSZ	12	ST
Zhao et al 2009 (31)	30	30	ETN	SSZ	6	ASAS 20, BASDAI, ST, ESR, CRP, AEs
Zhao et al 2009 (32)	43	43	ETN	SSZ	12	BASDAI, BASFI, ESR, CRP, AEs

ETN, etanercept; PBO, placebo; SSZ, sulfasalazine; ASAS, assessment in ankylosing spondylitis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; AE, adverse effect; OW, occiput-to-wall; ST, Schober’s test; PR, partial remission; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.